[Diagnosis and treatment of rheumatoid arthritis:toward the best practice. Change in immune phenotype by the treatment of rheumatoid arthritis.]
Considerable advance in the treatment of rheumatoid arthritis has been made following the advent of biological disease-modifying anti-rheumatic drugs that target TNF, IL-6 and co-stimulatory molecules. In addition, the introduction of molecular targeted drugs triggered accelerating translational research from the bedside to the bench. One example is immunophenotyping analysis using peripheral blood from patients. Accumulating evidences suggest that molecular targeted therapies induced different changes in different immune cell phenotypes involving both innate immunity and acquired immunity. Immunophenotypic analysis might be useful in evaluating the immune signatures and in predicting the therapeutic efficacy for individual patients.